Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-04-03

Study Completion Date

2024-03-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Isatuximab targets and kills CD38-positive myeloma cells in manner similar to rituximab's mechanism of action on CD20-positive lymphoma cells. Based on the synergy between rituximab and bendamustine, as well as the established clinical efficacy of bendamustine and isatuximab as single agents for multiple myeloma, the logical next step is to combine isatuximab with bendamustine and prednisone. Due to lack of effective therapies in refractory multiple myeloma, herein the investigators propose studying this novel combination in this population, in order to address a significant unmet need. The aim of the investigators is to first determine the maximal tolerated dose of the combination in participants with relapsed/refractory myeloma and then to establish the efficacy of this novel combination.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease

NCT04912427

Multiple Myeloma

TERMINATED PHASE1

Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma

NCT04892264

Plasma Cell Myeloma Recurrent Plasma Cell Myeloma Refractory Plasma Cell Myeloma

TERMINATED PHASE1

Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant

NCT03015792

Recurrent Plasma Cell Myeloma Refractory Plasma Cell Myeloma

TERMINATED PHASE1

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

NCT06785415

Recurrent Multiple Myeloma

RECRUITING PHASE1/PHASE2

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

NCT04270409

Plasma Cell Myeloma

ACTIVE_NOT_RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Myeloma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Phase I Dose Level 1: Isatuximab + Bendamustine + Prednisone

-Isatuximab (10 mg/kg) on Days 1, 8, 15, and 22 during Cycle 1 and on Days 1 and 15 of subsequent cycles. Bendamustine (50 mg/m\^2) will be administered on Days 1 and 2 and prednisone (60 mg) will be administered on Days 1 through 4 of each cycle.

Group Type EXPERIMENTAL

Isatuximab

Intervention Type BIOLOGICAL

Isatuximab will be administered on a 28-day cycle

Bendamustine

Intervention Type DRUG

Bendamustine will be administered on a 28-day cycle as follows

Prednisone

Intervention Type DRUG

Prednisone will be administered on a 28-day cycle as follows

Phase I Dose Level 2: Isatuximab + Bendamustine + Prednisone

-Isatuximab (10 mg/kg) on Days 1, 8, 15, and 22 during Cycle 1 and on Days 1 and 15 of subsequent cycles. Bendamustine (75 mg/m\^2) will be administered on Days 1 and 2 and prednisone (60 mg) will be administered on Days 1 through 4 of each cycle.

Group Type EXPERIMENTAL

Isatuximab

Intervention Type BIOLOGICAL

Isatuximab will be administered on a 28-day cycle

Bendamustine

Intervention Type DRUG

Bendamustine will be administered on a 28-day cycle as follows

Prednisone

Intervention Type DRUG

Prednisone will be administered on a 28-day cycle as follows

Phase I Dose Level 3: Isatuximab + Bendamustine + Prednisone

-Isatuximab (10 mg/kg) on Days 1, 8, 15, and 22 during Cycle 1 and on Days 1 and 15 of subsequent cycles. Bendamustine (100 mg/m\^2) will be administered on Days 1 and 2 and prednisone (60 mg) will be administered on Days 1 through 4 of each cycle.

Group Type EXPERIMENTAL

Isatuximab

Intervention Type BIOLOGICAL

Isatuximab will be administered on a 28-day cycle

Bendamustine

Intervention Type DRUG

Bendamustine will be administered on a 28-day cycle as follows

Prednisone

Intervention Type DRUG

Prednisone will be administered on a 28-day cycle as follows

Phase II: Isatuximab + Bendamustine + Prednisone

-Isatuximab (10 mg/kg) on Days 1, 8, 15, and 22 during Cycle 1 and on Days 1 and 15 of subsequent cycles. Bendamustine (dose determined in Phase I portion of study) will be administered on Days 1 and 2 and prednisone (60 mg) will be administered on Days 1 through 4 of each cycle.

Group Type EXPERIMENTAL

Isatuximab

Intervention Type BIOLOGICAL

Isatuximab will be administered on a 28-day cycle

Bendamustine

Intervention Type DRUG

Bendamustine will be administered on a 28-day cycle as follows

Prednisone

Intervention Type DRUG

Prednisone will be administered on a 28-day cycle as follows

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Isatuximab

Isatuximab will be administered on a 28-day cycle

Intervention Type BIOLOGICAL

Bendamustine

Bendamustine will be administered on a 28-day cycle as follows

Intervention Type DRUG

Prednisone

Prednisone will be administered on a 28-day cycle as follows

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Bendeka Treanda Deltasone Rayos Prednisone Intensol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of multiple myeloma with a measurable disease parameter at time of screening. A measurable disease parameter is defined as one or more of the following:

* Serum monoclonal protein ≥ 0.5 g/dL
* 24 hour urine monoclonal protein ≥ 200 mg/24 hour
* Serum free light chain ratio \> 5x normal ratio with an absolute difference of 10mg/dL between the involved and uninvolved free light chain
* Soft tissue plasmacytoma ≥ 2 cm measurable by either physical examination and/or applicable radiographs (e.g. MRI, CT, etc.)
* Bone marrow plasma cells ≥ 30%
* Triple-class-refractory disease defined as both of the following:

* Previously received treatment with a proteasome inhibitor, an immunomodulatory drug, and daratumumab, in combination or as single-agents.
* Refractory (defined per IMWG Consensus Criteria as disease that is nonresponsive while on therapy, or progresses within 60 days of last dose) to most recent therapy.
* At least 6 weeks from the last treatment with daratumumab to the first study treatment
* At least 18 years of age.
* Performance status of ECOG ≤ 2 Note: Participants with lower performance status based solely on bone pain secondary to multiple myeloma will be eligible.
* Normal bone marrow and organ function as defined as ALL of the following:

* Absolute neutrophil count ≥ 1500/mm3
* Platelets ≥ 75,000/mm\^3 (transfusions not permitted within 7 days of screening)
* ALT (SGPT) and AST (SGOT) \< 3.5 x the upper limit of the institutional normal value (ULN).
* Total bilirubin ≤ 2.0 x mg/dL.
* Creatinine clearance \> 30 ml/min using Cockcroft-Gault formula
* Females of childbearing potential (FCBP) must agree to refrain from becoming pregnant while on study drug and for 3 months after discontinuation from study drug, and must agree to use adequate contraception including hormonal contraception, (e.g. birth control pills, etc.), barrier method contraception (e.g. condoms), or abstinence during that time frame. Men engaging in sexual intercourse with a FCBP must agree to use adequate contraception including hormonal contraception, (e.g. birth control pills, etc), barrier method contraception (e.g. condoms), or abstinence while on study drug and for 3 months after discontinuation from study drug
* Ability to understand and willing to sign a written informed consent document.

Exclusion Criteria

* Prior exposure to isatuximab or bendamustine
* History of plasma cell leukemia or MM CNS involvement.
* Receiving renal replacement therapy, hemodialysis, or peritoneal dialysis.
* Diagnosed with another concurrent malignancy requiring treatment.
* Active hepatitis A, B, or C.
* Known intolerance to infused protein products, sucrose, histidine, polysorbate 80 or known hypersensitivity to any of the components of study therapy.
* Receiving any other investigational agents within 14 days prior to enrollment.
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
* Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.
* Patients with HIV are eligible unless their CD4+ T-cell counts are \< 350 cells/mcL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to registration. Concurrent treatment with effective ART according to DHHS treatment guidelines is recommended.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No